Precigen Names Rutul R. Shah Chief Operating Officer GERMANTOWN, MD

Rutul R. Shah Chief Operating Officer

September 21, 2022 - Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing

in the development of innovative gene and cell therapies to improve the lives of patients, today named Rutul R. Shah as the Company's

Chief Operating Officer (COO), effective October 1, 2022. Mr. Shah has been with the Company since 2014 and has served in roles of increasing

responsibility throughout his tenure, most recently as Head of Operations and Portfolio. In this newly created COO role, Mr. Shah will

have responsibility for strategic management of the Company's portfolio, and ensure agility and operational efficiency in executing

Company priorities while collaborating closely with Finance, Business Development and R&D. Mr. Shah will continue to report to Precigen's

President and CEO, Helen Sabzevari, PhD, and serve as a member of Precigen's leadership team.

Shah brings to the role more than 17 years of experience in the biopharmaceutical industry, of which 8 years have been focused exclusively

on innovations in gene and cell therapies. Mr. Shah has broad leadership experience and expertise in alliance management, portfolio management,

program and project management, and operations. Prior to joining Precigen, Mr. Shah spent a decade in scientific positions focused on

the development of protein and antibody drugs at Zyngenia, Teva Biopharmaceuticals USA, CoGenesys, and Human Genome Sciences. Mr. Shah

graduated with a BE degree in Chemical Engineering from Gujarat University in India and MS degree in Bioengineering from the University

of Illinois, Chicago.

contributions to Precigen have been instrumental in advancing the Company's portfolio with agility and operational efficiency,"

said Helen Sabzevari, PhD, President and CEO of Precigen. "Rutul brings an exceptional mix of scientific, clinical and business

expertise to his roles and is a highly respected and valued leader at the Company."

to be chosen as Precigen's first COO during this important time for the company," Mr. Shah said. "I look

forward to continuing to serve alongside the talented leadership team that Helen has assembled to achieve our goals."

Medicine with Precision

PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies

using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune

disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled

manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward

clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com

Cautionary Statement

Regarding Forward-Looking Statements

Some of the statements

made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations

and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's

business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise

of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the

plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve

risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19

pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking

statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties,

and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking

statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent

reports filed with the Securities and Exchange Commission.